The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder
Abstract
OBJECTIVE: This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety disorder without concomitant major depressive disorder. METHOD: Adult outpatients with generalized anxiety disorder but not major depressive disorder with total scores of 18 or higher on the Hamilton Rating Scale for Anxiety and scores of 2 or higher on its anxious mood and tension factors were eligible. Patients were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks. Primary efficacy variables were final total and psychic anxiety factor scores on the Hamilton anxiety scale and final severity and global improvement item scores on the Clinical Global Impression (CGI) scale. RESULTS: Of the 377 patients entering the study, 370 were included in a safety analysis and 349 in an efficacy analysis. Adjusted mean scores at 8 weeks (last-observation-carried-forward analysis) were significantly lower for one or more of the venlafaxine XR groups in four of four primary and three of four secondary outcome measures than for the placebo group. These included a change of 1.7 (versus 1.3) from baseline on CGI severity item scores and a final score of 2.2 (versus 2.6) on the CGI global improvement item. All doses of venlafaxine XR were well tolerated. CONCLUSIONS: Venlafaxine XR is an effective and well-tolerated option for the short-term treatment of generalized anxiety disorder in outpatients without major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412
Self-citationRASKIN, A., SCHULTERBRANDT, J., REATIG, N., & McKEON, J. J. (1969) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196901000-00010 · Cited by 373
Kahn, R. J. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800010081010 · Cited by 278
Phenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242 · cited 2×
“lengths of 20 years have been reported [3, 4]), and has a low”
BackgroundPsychiatric comorbidity in patients with generalized anxiety disorder
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1216 · Cited by 200
Paroxetine efficacy in the treatment of generalized anxiety disorder
Rocca, P., Fonzo, V., Scotta, M., Zanalda, E., & Ravizza, L. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09660.x · Cited by 194
Generalized anxiety and generalized anxiety disorder: description and reconceptualization
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.40 · Cited by 181
Hoehn‐Saric, R., McLeod, D. R., & Zimmerli, W. D. (1988) · PubMed · Cited by 156
Differentiating anxiety and depression in anxiety disorders: use of rating scales.
Lipman, R. S. (1982) · PubMed · Cited by 119
Design and analysis of single-factor experiments.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-003 · Cited by 84
Comorbidity of anxiety, phobia, compulsion and depression
Angst, J. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199309001-00003 · Cited by 76
Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients
Laakmann, G., Schüle, C., Lorkowski, G., Baghai, T. C., Kuhn, K., & Ehrentraut, S. (1998) · Psychopharmacology · doi:10.1007/s002130050578 · Cited by 75
A Meta-Analysis of the Effects of Venlafaxine on Anxiety Associated With Depression
Rudolph, R. L., Entsuah, R., & Chitra, R. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804000-00006 · Cited by 73
Feighner, J. P., Entsuah, A. R., & McPherson, M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00109-2 · Cited by 64
Generalized anxiety disorder: issues in epidemiology.
Brawman‐Mintzer, O., & Lydiard, R. B. (1996) · PubMed · Cited by 58
Biological basis of generalized anxiety disorder.
Brawman‐Mintzer, O., & Lydiard, R. B. (1997) · PubMed · Cited by 55
Generalized anxiety disorder: new concepts and psychopharmacologic therapies.
Dubovsky, S. L. (1990) · PubMed · Cited by 54
An open trial of nefazodone in adult patients with generalized anxiety disorder.
Dw, H., Reimherr, F. W., Re, S., Ch, H., & Rust, C. (1996) · PubMed · Cited by 51
Venlafaxine in depressed geriatric outpatients: an open-label clinical study.
Khan, A., Rudolph, R. L., Baumel, B. S., Ferguson, J. M., Ryan, P. P., & Shrivastava, R. K. (1995) · PubMed · Cited by 28
Economic costs of anxiety disorders
DuPont, R. L., Rice, D. P., Miller, L. S., Shiraki, S. S., Rowland, C. R., & Harwood, H. J. (1996) · Anxiety · doi:10.1002/(sici)1522-7154(1996)2:4<167::aid-anxi2>3.0.co;2-l
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Metadata
- Authors
- Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T.
- Venue
- American Journal of Psychiatry
- Published
- 2000-06-01
- Volume
- 157
- Issue
- 6
- Pages
- 968-974
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2084977025
- Cited by
- 252
- References
- 24
- FWCI
- 30.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.